Hostname: page-component-74656f9884-rdgjk Total loading time: 0 Render date: 2026-11-07T20:34:43.241Z Has data issue: false hasContentIssue false

The prophylactic and therapeutic impact of Trichinella spiralis larvae excretory secretory antigens- loaded Ca-BTC metal organic frameworks on induced murine colitis

Published online by Cambridge University Press:  24 May 2024

E.M. Fawzy
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Sharkia, Egypt
M.A. Selim
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Sharkia, Egypt
N. E. Mostafa
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Sharkia, Egypt
R.M. Abdelhameed
Affiliation:
Department of Applied Organic Chemistry, National Research Centre, Dokki, Giza, Egypt
A.M. Darwish
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Sharkia, Egypt
A.M. Yousef
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Sharkia, Egypt
M.A. Alabiad
Affiliation:
Department of Pathology, Faculty of Medicine, Zagazig University, Egypt
M.N. Ibrahim
Affiliation:
Department of Clinical Laboratories, College of applied Medical Sciences, Jouf University, Qurrayat 77451, KSA
H.M. Fawzy
Affiliation:
Department of Community, Faculty of Medicine, Zagazig University, Sharkia, Egypt
E.F. Abdel Hamed*
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Sharkia, Egypt
*
Corresponding author: E.F. Abdel Hamed; Email: drenasfakhry@gmail.com
Rights & Permissions [Opens in a new window]

Abstract

Background: Inflammatory bowel disease is an autoimmune disease that affects the gut. T. spiralis larvae (E/S Ags) loaded on calcium-benzene-1,3,5-tricarboxylate metal-organic frameworks (Ca-BTC MOFs) were tested to determine whether they might prevent or cure acetic acid-induced murine colitis. Methods: T. spiralis larvae E/S Ags/Ca-BTC MOFs were used in prophylactic and therapeutic groups to either precede or follow the development of murine colitis. On the seventh day after colitis, mice were slaughtered. The effect of our target antigens on the progress of the colitis was evaluated using a variety of measures, including survival rate, disease activity index, colon weight/bodyweight, colon weight/length) ratios, and ratings for macroscopic and microscopic colon damage. The levels of inflammatory cytokines (interferon-γ and interleukin-4), oxidative stress marker malondialdehyde, and glutathione peroxidase in serum samples were evaluated. Foxp3 T-reg expression was carried out in colonic and splenic tissues. Results: T. spiralis larvae E/S Ags/Ca-BTC MOFs were the most effective in alleviating severe inflammation in murine colitis. The survival rate, disease activity index score, colon weight/length and colon weight/bodyweight ratios, and gross and microscopic colon damage scores have all considerably improved. A large decrease in proinflammatory cytokine (interferon-γ) and oxidative stress marker (malondialdehyde) expression and a significant increase in interleukin-4 and glutathione peroxidase expression were obtained. The expression of Foxp3+ Treg cells was elevated in colonic and splenic tissues. Conclusion: T. spiralis larvae E/S Ags/Ca-BTC MOFs had the highest anti-inflammatory, antioxidant, and cytoprotective capabilities against murine colitis and might be used to develop new preventative and treatment strategies.

Information

Type
Research Paper
Copyright
© The Author(s), 2024. Published by Cambridge University Press
Figure 0

Figure 1. a: FTIR of Ca-BTC used that the BTC molecule is linked to Ca ions, and the C=O stretching frequency of free aromatic carboxylic acid is shifted to lower frequencies (Ca. 1550 cm-1).; b: thermogravimetric analysis of Ca-BTC was used to characterise its thermal stability. Three weight-loss phases of Ca-BTC MOFs were obtained as the temperature increased (25–800°C). The weight loss in step 3 (450°C-700°C) can be attributed to calcium oxide production as the temperature rises. Ca-BTC has a BET-specific surface area of 376.805 m2 g-1 and a pore size of 1.68 nm. c: The equilibrium between the concentrations of the various antigens and the loading quantity. d: The maximum antigen loading was attained at 100 minutes. e: E/S Ags/Ca-BTC TEM pictures after antigen loading, the morphology of the nanoparticle changed significantly, with the E/S Ags appearing as white dots surrounding the Ca-BTC particles. f: Kaplan-Meier curves prophylactic. g: Kaplan-Meier curves among therapeutic groups. h: CW/BW ratio (prophylactic and Therapeutic groups). i: CW/L ratio (prophylactic and Therapeutic groups). Results are representative as means ± SD (h,i). * P < 0.05, ** P < 0.01, *** P < 0.001.

Figure 1

Table 1. Weight changes and DAI score at different times after colitis induction

Figure 2

Figure 2. Representative photomicrographs of mouse colons at 7 days post-colitis. a: The control negative group has an apparently normal colonic wall (green arrows). b: Colitis model demonstrating characteristic large hemorrhagic area with perforation (blue arrows) of the colonic wall, edema, and congestion (yellow arrows); Prophylactic groups: c: the colon of mice that received Ca-BTC showed edema (yellow arrow) and congestion (black arrow); d: Mice that received T. spiralis larvae E/S Ags showed residual edema in the colonic wall without congestion (green and red arrows). e: Mice that received T. spiralis larvae E/S Ags Ca-BTC had a normal colonic wall (green arrow); Therapeutic groups: f: Mice that received Ca-BTC had a continuous large hemorrhagic area, edema, and congestion in the colonic wall (red arrows). g: Mice that received T. spiralis larvae E/S Ags showed a minor hemorrhagic area and lesser congestion with edema (green arrows). h: Mice that received T. spiralis larvae E/S Ags/Ca BTC (X200) showed fewer edematous changes (green arrow) with decreased congestion (black arrow). i: Macroscopic score of prophylactic and therapeutic. Results are representative as means ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001.

Figure 3

Figure 3. Histopathological examination of the colon sections of prophylactic groups 7 days postcolitis. a: microscopic scores of the prophylactic and therapeutic groups. Results are representative as means ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001. b: Negative control group. c: Colitis models: severe mucosal, submucosal, and transmural inflammation and damaged tissue architecture. d: mice received Ca-BTC: focal erosion (black arrow), dense infiltration (yellow arrow). e: mice treated with T. spiralis larvae E/S Ags: mild transmural inflammation (black arrow). f: mice received T. spiralis larvae E/S Ags-Ca-BTC/MOFs had relatively normal intestine and late regenerative changes. Colon sections of therapeutic groups at 7 days postcolitis. g: mice received Ca-BTC: deep mucosal neutrophilic cellular infiltration of the intestinal wall (yellow arrow); focal crypt abscess (black arrow); h: mice treated with T. spiralis larvae E/S Ags: marked mucosal and submucosal aggregation of mixed inflammatory cells (blue arrow) with marked superficial erosion (black arrow); moderate submucosal edema (red arrow); i: T. spiralis larvae E/S Ags-Ca-BTC/MOFs: mild mucosal infiltration of mononuclear inflammatory cells with mild interstitial edema and vascular congestion.

Figure 4

Figure 4. Inflammatory cytokines in the prophylactic and therapeutic groups: a: IFN-γ; b: IL-4. Oxidative stress parameters: c: MDA1; d: GPX. Results are representative as means ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Figure 5

Figure 5. Immunohistochemically stained photomicrographs with anti-Foxp3+ antibody of colon tissues 7 days postcolitis among prophylactic groups. a: Fox-colon expression of the prophylactic and therapeutic. Results are representative as means ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001. b: Control the negative group. c: Colitis model immune-stained with anti-Foxp3 antibody showing positive cells. Prophylactic group: d: Mice received Ca-BTC immune-stained with anti-Foxp3 antibody showing mild expression. e: Mice were treated with E/S Ags immune-stained with anti-Foxp3 antibody showing moderate immunoreactivity of Foxp3 antibody. f: Mice were treated with T. spiralis larvae E/S Ags/Ca BTC MOFs immune-stained with anti-Foxp3 antibody showing strong immunoreactivity of Foxp3 antibody. Therapeutic group: g: mice received Ca-BTC immune-stained with anti-Foxp3 antibody, showing positive cells. h: mice were treated with T. spiralis larvae E/S Ags immune-stained with anti-Foxp3 antibody, showing mild immunoreactivity of Foxp3 antibody; i: mice were treated with T. spiralis larvae E/S Ags/Ca-BTC MOFs immune-stained with anti-Foxp3 antibody, showing moderate immunoreactivity of Foxp3 antibody.

Figure 6

Figure 6. Results of immunohistochemically stained photomicrographs with an anti-Foxp3+ antibody of splenic tissues 7 days postcolitis among prophylactic groups. a: Fox-spleen expression of the prophylactic and therapeutic. Results are representative as mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001. b: Control normal group showing negative immunoreactivity in all lymphoid cells of both the white and red pulp. c: Colitis model: showing positive immune-stained cells with an anti-Foxp3 antibody; Prophylactic groups: d: Mice received Ca-BTC MOFs, showing mild immunoreactivity of Foxp3 antibody; e: Mice treated with T. spiralis larvae E/S Ags showed moderate immunoreactivity of Foxp3 antibody; f: Mice treated with T. spiralis larvae E/S Ags/Ca BTC MOFs revealed marked immunoreactivity to the used marker. Therapeutic group: g: Mice received Ca-BT MOFs showing positive cells; h: Mice treated with T. spiralis larvae E/S Ags showed moderately mild immunoreactivity of the Foxp3 antibody; i: Mice treated with T. spiralis larvae E/S Ags/Ca BTC MOFs showed moderate immunoreactivity to the used marker.

Figure 7

Table 2. Liver and kidney function tests 7 days after AA-induced colitis